Long-acting local anesthetic formulation
AssigneeUniversity of Connecticut
InventorsRajesh V. Lalla, Diane J. Burgess, Tingting Li
Life of this patent
Estimating the term…
Abstract
Compositions that include a bupivacaine salt are provided. The compositions may include bupivacaine linoleate, bupivacaine linolenate or bupivacaine laurate, at least one thermosensitive polymer, and at least one mucoadhesive or dermoadhesive agent. Also provided are methods for the treatment of an inflammatory or ulcerative condition with the disclosed compositions.
Claims12
A method for treating a subject suffering from oral mucositis, aphthous stomatitis, pemphious vulgaris, or mucous membrane pemphigoid, the method comprising the step of administering to a subject suffering from oral mucositis, aphthous stomatitis, pemphigus vulgaris, or mucous membrane pemphigoid, a therapeutically effective amount of an oral spray formulation comprising an anesthetic, at least one thermosensitive polymer, and a mucoadhesive or dermoadhesive agent, wherein the anesthetic comprises bupivacaine hydrochloride and the mucoadhesive or dermoadhesive agent comprises carboxymethylcellulose and further wherein:
- (a) the concentration of bupivacaine hydrochloride in the formulation is about 0.05% weight/volume (w/v) to about 5% w/v of the formulation;
- (b) the concentration of at least one thermosensitive polymer is about 10% w/v to about 22% w/y of the formulation;
- (c) the concentration of the mucoadhesive or dermoadhesive agent is about 0.05% w/y to about 5% w/y of the formulation;
- and (d) the thermosensitive polymer comprises poloxamer 407, poloxamer 188, or a combination thereof.
Dependencies are inferred from the claim text.